Division of Nephrology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Department of Medical Microbiology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Semin Dial. 2022 May;35(3):264-268. doi: 10.1111/sdi.13049. Epub 2022 Jan 6.
As end-stage renal disease (ESRD) patients generally have reduced responses to the vaccines, effectiveness of newly developed SARS-CoV-2 vaccines in ESRD are also matters of curiosity. We aimed to investigate the humoral responses of our peritoneal dialysis (PD) patients to the inactivated SARS-CoV-2 vaccine.
Humoral immune responses of 23 PD patients who received two doses of the inactivated SARS-CoV-2 vaccine were investigated with a commercial test that measures IgG antibodies towards receptor binding domain of SARS-CoV-2 spike protein. Seropositivity rates, antibody titers, and ESRD related clinical data were compared with 51 hemodialysis (HD) patients and 29 healthy volunteers.
Seropositivity of PD patients with the inactivated vaccine was 95.6%. Both the rate of seropositivity and SARS-CoV-2 IgG antibody levels in PD patients were not different from the healthy controls (p = 0.85 and 0.19, respectively). While seropositivity rates were not different for PD or HD patients (p = 0.09), the magnitude of humoral responses was significantly higher in PD patients (p = 0.0001). There were no vaccine-related serious adverse events. In the 3-months clinical follow-up, none of the patients experienced SARS-CoV-2 infection.
Two doses of the inactivated vaccine generate adequate humoral immune response in PD patients without any serious adverse events.
由于终末期肾病（ESRD）患者对疫苗的反应通常减弱，因此新开发的 SARS-CoV-2 疫苗在 ESRD 患者中的有效性也是人们关注的问题。我们旨在研究我们的腹膜透析（PD）患者对灭活 SARS-CoV-2 疫苗的体液免疫反应。
用商业检测试剂盒检测 23 名接受两剂灭活 SARS-CoV-2 疫苗的 PD 患者针对 SARS-CoV-2 刺突蛋白受体结合域的 IgG 抗体的体液免疫反应。将血清阳性率、抗体滴度和 ESRD 相关临床数据与 51 名血液透析（HD）患者和 29 名健康志愿者进行比较。
PD 患者对灭活疫苗的血清阳性率为 95.6%。PD 患者的血清阳性率和 SARS-CoV-2 IgG 抗体水平与健康对照组无差异（p=0.85 和 0.19）。虽然 PD 或 HD 患者的血清阳性率无差异（p=0.09），但 PD 患者的体液反应幅度明显更高（p=0.0001）。没有与疫苗相关的严重不良事件。在 3 个月的临床随访中，没有患者感染 SARS-CoV-2。
两剂灭活疫苗可在 PD 患者中产生足够的体液免疫反应，且无任何严重不良事件。
